Craig Rayner Biography and Net Worth

Insider of Certara

Dr. Rayner is President of Certara’s Integrated Drug Development and Strategic Consulting Services. In this capacity, he supports a global team of clinical and quantitative pharmacologists, pharmacometricans, regulatory strategy and drug development scientists who create value for clients across the drug development ecosystem and ultimately accelerate patients’ access to medicines.

Craig has extensive global experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous due diligences, active support of negotiations, deal making and integration activities.

Previously, Craig was the Co-founder and CEO of d3 Medicine. Prior to that, Craig’s appointments included leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche), and in clinical pharmacology and infectious disease research (Monash University).

Craig holds an Adjunct Associate Professorship in Pharmaceutical Science (Monash University), is a Distinguished Alumni of the Faculty of Pharmacy and Pharmaceutical Sciences (Monash University), has broadly published in clinical pharmacology and also infectious diseases.

What is Craig R. Rayner's net worth?: The estimated net worth of Craig R. Rayner is at least $3.93 million as of September 2nd, 2021. Dr. Rayner owns 366,572 shares of Certara stock worth more than $3,925,986 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Rayner may own. Learn More about Craig R. Rayner's net worth.
How do I contact Craig R. Rayner?: The corporate mailing address for Dr. Rayner and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Craig R. Rayner's contact information.
Has Craig R. Rayner been buying or selling shares of Certara?: Craig R. Rayner has not been actively trading shares of Certara in the last ninety days. Most recently, Craig R. Rayner sold 54,462 shares of the business's stock in a transaction on Thursday, September 2nd. The shares were sold at an average price of $36.33, for a transaction totalling $1,978,604.46. Following the completion of the sale, the insider now directly owns 366,572 shares of the company's stock, valued at $13,317,560.76. Learn More on Craig R. Rayner's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, insiders at the sold shares 6 times. They sold a total of 86,060 shares worth more than $1,151,075.18. The most recent insider tranaction occured on October, 7th when insider Patrick F Smith sold 5,409 shares worth more than $59,661.27. Insiders at Certara own 2.4% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 10/7/2024.

Craig R. Rayner Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/2/2021	Sell	54,462	$36.33	$1,978,604.46	366,572
6/11/2021	Sell	108,924	$25.71	$2,800,436.04	416,951

Craig R. Rayner Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $10.71

$10.51

$11.05

50 Day Range

MA: $10.81

$9.55

$11.71

2 Week Range

Now: $10.71

$9.41

$19.87

Volume

3,240,121 shs

Average Volume

852,739 shs

Market Capitalization

$1.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.